A panel of experts published new recommendations for assessing and managing CVD risk while treating patients with prostate cancer.
The Prostate Cancer Cardiovascular (PCCV) Expert Network recently published recommendations to guide prostate cancer care strategies. The guidance centers on how clinicians can assess cardiovascular disease (CVD) risk and implement multidisciplinary care for their patients.
“The European Society of Cardiology (ESC) 2022 Guidelines on Cardio-Oncology recommend gonadotropin-releasing hormone antagonists for patients with pre-existing coronary artery disease who require androgen deprivation therapy,” wrote Axel S. Merseburger, MD, PhD, lead author, and colleagues. “However, real-world data show that gonadotropin-releasing hormone antagonists are not widely adopted in practice, indicating a gap between guidelines and practice that should be bridged by prioritizing cardioprotection.”
The team of experts included 14 urologists, three cardiologists, and one medical oncologist. They identified the following barriers to routine CVD risk assessment and management:
- lack of awareness regarding cardiovascular toxicities associated with androgen deprivation therapy…
